Cormedix Inc. 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on June 27, 2012, by Cormedix Inc., a Delaware corporation. The report addresses a significant corporate governance event regarding the company's listing status on the NYSE-Amex.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document references a prior determination by the NYSE-Amex that the Company had sustained substantial losses and an impaired financial condition, but no quantitative financial data is included in this specific report.
Material Changes and Events
- Listing Compliance Status: The NYSE-Amex notified the Company on June 27, 2012, that it is not currently in compliance with Section 1003(a)(iii) of the AMEX Company Guide due to substantial losses and impaired financial condition.
- Compliance Plan Approval: The NYSE-Amex accepted the Company's plan to regain compliance, submitted on May 17, 2012.
- Extension Granted: The exchange determined the Company made a reasonable demonstration of its ability to regain compliance by the end of the plan period, August 22, 2012.
- Continued Listing: The Company's listing is being continued pursuant to an extension, subject to periodic review.
Outlook, Risks, and Management Commentary
Management, represented by Interim CEO and CFO Richard M. Cohen, notes that there can be no assurance the Company will make progress consistent with the plan or regain compliance in a timely manner. The primary risk identified is potential delisting from the NYSE-Amex if the Company fails to make progress consistent with the plan or fails to regain compliance by the August 22, 2012 deadline.
Investor Verification Checklist
- Verify the specific financial metrics and operational milestones outlined in the compliance plan submitted on May 17, 2012.
- Monitor the Company's progress reports during the extension period ending August 22, 2012.
- Review the press release filed as Exhibit 99.1 for additional details on the compliance strategy.
- Assess the Company's ability to generate revenue or secure financing to address the "substantial losses" cited by the exchange.